Viva In Vitro

What Viva In Vitro does

Viva In Vitro Diagnostics, S.L. is a Spanish biotech founded in 2021 as the first spin-off of the Instituto Murciano de Investigación Biomédica (IMIB) and the University of Murcia, headquartered in the Murcia Science Park. The company develops diagnostic and research products built on proprietary NLRP3 inflammasome detection technology that quantifies ASC-Speck formation in myeloid cells via ex vivo blood stimulation, originally derived from the ERC SPEDI-TEST project. Its commercial pipeline centers on three assets: VIVA-ELISA® (a clinical-grade ELISA for sepsis prognosis and patient immune stratification, targeting TRL6), VIVA ELISA® RUO (a research-use-only kit scheduled for Q4 2025 launch), and VIVA SEPS CARE® (an automated random-access hospital device under evaluation for market entry).

The company's commercial model is multi-pronged: B2B sales of diagnostic kits and devices to hospitals and clinical laboratories following EU IVDR Class C and US FDA 510(k) approvals; fee-for-service offerings to pharmaceutical and biotech companies including NLRP3 compound screening, biomarker validation, and clinical-trial patient stratification support; and potential licensing royalties on NLRP3-related diagnostics and therapeutics. Primary customer segments are pharmaceutical companies and hospitals/ICU departments, with secondary segments in biotech firms and academic research centers. Go-to-market is sales-led, supplemented by conference presence (e.g., 9º Encuentro Internacional Código Sepsis) and thought-leadership channels such as the VIVA Insights newsletter. Clinical validation is in progress with 158 patients already validated and 360+ patients enrolled across five leading Spanish hospitals, with management and scientific direction led by CEO Toni Vilaplana, Executive President Joaquín Gómez Moya, and scientific founder Dr. Pablo Pelegrín.

Name

Viva In Vitro

Legal name

VIVA IN VITRO DIAGNOSTICS, S.L.

Website

https://vivaivd.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Viva In Vitro is a Spanish biotech developing proprietary NLRP3 inflammasome diagnostics, anchored by VIVA-ELISA® for early sepsis prognosis and patient stratification, serving pharmaceutical companies, hospitals, and research centers.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro industry

PRIMARYHLAAALAH

Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLAGAEAB

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

SECONDARYHLAGAEAE

Clinical Chemistry, Hematology & Coagulation Testing (Trial Support)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

• In vitro diagnostics
• Sepsis diagnostics
• NLRP3 inflammasome detection
• Biomarker assay development
• Clinical immunoassays

Headquarters

HQ city

Murcia

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. VIVA-ELISA® Diagnostic Products: Sale of ELISA-based diagnostic kits for NLRP3 inflammasome detection in clinical settings. VIVA ELISA® RUO (Research Use Only) planned for Q4 2025 launch, clinical-grade VIVA ELISA® planned for 2028 with FDA/CE certification.
2. VIVA SEPS CARE® Device: Sale of automated random access diagnostic devices for hospitals and clinical laboratories. Device under evaluation for market entry.
3. Pharmaceutical Industry Services: Specialized inflammasome services for pharmaceutical and biotech companies including compound screening, biomarker validation, clinical trial support, patient stratification, and therapeutic development partnerships.
4. Licensing Royalties: Technology licensing opportunities for NLRP3-related diagnostics and therapeutics to pharmaceutical companies developing inflammasome-targeted treatments.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Viva In Vitro develops and commercializes proprietary NLRP3 inflammasome-based diagnostic products and services for sepsis prognosis and patient stratification. Its core product, VIVA-ELISA®, is the first clinical ELISA for detecting NLRP3 inflammasome activation via the ASC-Speck biomarker in critically ill patients. The company also offers VIVA ELISA® RUO for research use, the VIVA SEPS CARE® automated hospital device, and specialized services including compound screening, biomarker validation, and clinical trial support for pharmaceutical and biotech clients.

Product overview

Viva In Vitro offers a portfolio of diagnostic products and services focused on NLRP3 inflammasome detection for sepsis and inflammatory diseases. The core product is VIVA-ELISA®, a pioneering clinical ELISA for early sepsis prognosis. Supporting this are VIVA ELISA® RUO (research use version launching Q4 2025) and VIVA SEPS CARE® (automated hospital device under evaluation). The company also provides specialized services for pharmaceutical and biotech companies including compound screening, translational validation, and clinical trial biomarker design.

Differentiator

Problem solved

Functional benefit

Brands

• VIVA-ELISA®: Advanced diagnostic technology for early detection of NLRP3 inflammasome activation in critically ill septic patients, based on ASC-Speck detection.
• VIVA SEPS CARE®
• Viva Sepscare®
• Viva Elisa®

Products and services

• VIVA-ELISA®
• VIVA ELISA® RUO
• VIVA SEPS CARE®
• Pharmaceutical and Biotech Inflammasome Services

Quantifiable outcome

• Reduce sepsis mortality by 25-40% through early screening
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Instituto Murciano de Investigación Biomédica (IMIB)coreStrategic or Co-development PartnerParent research institution spin-off relationship. Dr. Pablo Pelegrín serves as Deputy Scientific Director. Provides laboratory facilities, clinical trial sites (Hospital Arrixaca), and research collaboration. Initial technology developed from ERC SPEDI-TEST project conducted at IMIB.
• Hospital Clínico Universitario Virgen de la ArrixacacoreStrategic or Co-development PartnerKey clinical validation partner. Dr. Carlos García Palenciano (Head of Anesthesiology) serves as Clinical Director and Founder. Primary site for Proof of Concept clinical trials. Led by Dr. Piedad Martínez Gil (Anesthesia and Resuscitation Department).
• Hospital Universitari Vall d'HebroncoreStrategic or Co-development PartnerClinical trial partner with Dr. Ricard Ferrer Roca as Principal Investigator (Head of Intensive Care). Prof. Ignacio Martín-Loeches serves as External Advisor. Leader of SODIR research group. Premier research hospital in Barcelona.
• Hospital Clínic Universitari de ValènciacoreStrategic or Co-development PartnerClinical validation partner with Dr. Gerardo Aguilar Aguilar (Head of Critical Care Unit, Department of Anesthesiology and Resuscitation). Key site for sepsis research and patient validation studies.
• Hospital Universitario Virgen de la Victoria de MálagacoreStrategic or Co-development PartnerClinical trial partner with Dr. Elena Giráldez Vázquez (Intensive Care Specialist) and Dr. María Antonia Estecha (Head of Intensive Care Medicine Service). Part of Servicio Andaluz de Salud network.
• Dr. Mihai NeteacoreStrategic or Co-development PartnerMember of International Scientific Advisory Committee. Head of Division of Experimental Medicine at Radboud University Medical Center, Netherlands. One of most cited authors in immunology, specializing in infectious diseases and innate immunity. Leads Immunosep project on personalized sepsis treatment.
• Dr. Eduardo López CollazocoreStrategic or Co-development PartnerMember of International Scientific Advisory Committee. Deputy Scientific Director of Health Research at Hospital Universitario de la Paz, Spain. Expert in sepsis, cancer, leukemia, cystic fibrosis, HIV and COVID-19 research.
• Dr. Rebecca CollcoreStrategic or Co-development PartnerMember of International Scientific Advisory Committee. Queen's University Belfast, UK. Leader in inflammasome research and NLRP3 inhibitor characterization. Led biological characterization of MCC950, impacting Alzheimer's, Parkinson's, MS, and atherosclerosis research.
• Prof. Ignacio Martín-LoechescoreStrategic or Co-development PartnerMedical Advisory Board Lead Coordinator. Professor at Trinity College Dublin and Consultant at St James's Hospital, Europe. Former President of SEMICYUC, expert in intensive care medicine and sepsis.
• Trinity College DublinminorStrategic or Co-development PartnerAcademic partnership through Prof. Ignacio Martín-Loeches. Ireland's leading research institution in intensive care medicine and sepsis research.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Prenosis: AI-driven diagnostics company (Sepsis ImmunoScore) that combines biomarkers and clinical data to predict sepsis. Comparable as a technology-forward sepsis diagnostics company pursuing host-response-based patient stratification in hospital settings.
• Cytovale: Developer of IntelliSep, an FDA-cleared cellular biomarker test for early sepsis diagnosis in ED/ICU settings. Comparable as an emerging competitor using novel biomarker approaches to address the same sepsis early-diagnosis clinical problem.
• SphingoTec: German diagnostics company developing novel blood biomarkers for critical care, including sepsis (penKid, bio-Adrenomedullin). Comparable as a peer commercializing novel biomarker-based diagnostics for ICU and critical-care decision making.
• Bühlmann Laboratories: Swiss specialty diagnostics company with strong ELISA and inflammatory biomarker portfolio (e.g., calprotectin, pancreatic elastase). Comparable as a specialty IVD company selling research-use and clinical ELISA kits to pharma/biotech and hospital labs.

Broad incumbents

• bioMérieux: Global leader in microbiology and clinical diagnostics, including sepsis diagnostics (e.g., BACT/ALERT, VITEK). Directly comparable as the dominant incumbent in the same sepsis diagnostics market Viva In Vitro targets, with established hospital sales channels and regulatory expertise.
• Roche Diagnostics: Largest IVD company globally, with Elecsys sepsis and infectious disease menu and broad hospital lab footprint. Comparable as a broad incumbent whose installed cobas/e601 platforms represent both the existing standard of care and a potential channel for partnerships or competing assays.
• Beckman Coulter Diagnostics: Major IVD manufacturer with broad sepsis and hematology menu including DxH hematology analyzers and clinical chemistry platforms. Comparable as an established IVD company whose installed base in hospital labs represents both the channel and the competitive threat for Viva In Vitro's VIVA SEPS CARE® device.

Direct peers

• T2 Biosystems: US-listed diagnostics company developing rapid molecular diagnostics for sepsis (T2Bacteria, T2Candida). Directly comparable as a focused sepsis diagnostics company selling novel biomarker-based tests to hospitals and competing for similar clinical decision-making workflows.
• Immunexpress: Australian/US company developing SeptiCyte (host-response gene expression test for sepsis). Directly comparable as a peer focused on host immune response diagnostics for sepsis prognosis, with cleared or in-clearance products competing in the same clinical decision space.
• Inflammatix: US-based diagnostics company using host immune response (including inflammasome-related pathways) for acute infection and sepsis diagnosis. Closely comparable as a direct peer building immune-based diagnostics for sepsis prognosis and patient stratification.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/viva-in-vitro

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viva In Vitro